CAR-T Cell Therapy for Multiple Sclerosis: A Systematic Review of Emerging Clinical, Safety, and Biomarker Evidence (P11-19.002)

June 9, 2026Neurology

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate how effective and safe CAR T-cell therapy is for treating multiple sclerosis, along with its effects on biomarkers.
A systematic review of current clinical trials and studies on CAR T-cell therapy for multiple sclerosis was conducted.
Data on efficacy, safety, and biomarker impacts were analyzed from various emerging clinical evidence.
Findings suggest promising efficacy of CAR T-cell therapy in reducing MS symptoms, though comprehensive safety data are still emerging.
Biomarker analyses indicate potential markers correlated with treatment response, but further validation is needed.

Systematic review evaluates CAR-T cell therapy outcomes in multiple sclerosis, highlighting its safety and biomarker implications.

To systematically evaluate the efficacy, safety, and biomarker effects of chimeric antigen receptor (CAR) T-cell therapy in multiple sclerosis (MS).

No takes yet. Share an insight, caveat, or question.

Lima et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share